FULL YEAR REPORT 2016
THE FULL YEAR AND THE FOURTH QUARTER · Net sales amounted to MSEK 347.3 (69.1), whereof the fourth quarter MSEK 96.5 (57.4) · EBITDA was MSEK 51.7 (-71.7), whereof the fourth quarter MSEK 28.9 (-22.3) · Earnings per share amounted to SEK 1.51 (-1.46), whereof the fourth quarter SEK 1.36 (-0.46) · Cash and cash equivalents at period end amounted to MSEK 121.3 (76.5) · Acquisition of BioPhausia with a well established portfolio of drugs · A long term credit facility has been signed in conjunction with the acquisition of BioPhausia · KB9520 was outlicensed to the cancer